Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...

Stock index futures erased their earlier gains on Friday, as the PCE report came in hotter than expected. Here are the four ...

・The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3. ・Pfizer’s BioNTech position was reduced by 54.7%, leaving ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation ...

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.

FRANKFURT (Reuters) -BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer is looking to sell its stake in the German biotech firm ...

Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 ...

Pfizer PFE reported fourth-quarter 2025 adjusted earnings per share of 66 cents, which comprehensively beat the Zacks Consensus Estimate of 57 cents per share. Earnings rose 5% year over year.

BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product ...